DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Cannabis Stocks on Nasdaq: Cronos, Canopy Growth and Tilray Rebuild the Global Cannabis Trade Around Medical Markets, Europe and Balance Sheet Discipline $CRON $CGC $TLRY
The cannabis trade is no longer the same speculative legalization trade that dominated the previous cycle. Cronos, Canopy Growth and Tilray now represent three different Nasdaq-listed cannabis reset stories: one balance-sheet name, one turnaround catalyst name, and one diversified global medical and consumer platform.
Okta Inc. (Nasdaq: $OKTA): Identity Security, AI Agents And The Cash-Flow Re-Rating Test
Merlintrader Deep Dive Cybersecurity AI Agents Cash Flow Re-Rating Microsoft Competition Risk “` Okta Inc. (Nasdaq: $OKTA): Identity Security, AI Agents And The Cash-Flow Re-Rating Test Okta is no longer a pure hypergrowth SaaS story. After Q1 FY2027, the cleaner…
Replimune Group (Nasdaq: $REPL): RP1 Gets A Third FDA Opening After The Second CRL
Replimune’s May 29, 2026 announcement reopens one of the most controversial oncology regulatory stories of the year. RP1 is not approved, and a new PDUFA date has not yet been announced, but the company says FDA has aligned on a path for resubmission and urgent reconsideration of the BLA for RP1 plus nivolumab in advanced melanoma.
U.S. Drone Funding Talks: What the Rumor Really Means for $UMAC, $RCAT, $ONDS, $KTOS and $AVAV
Clean read: the rumor is not the same for every ticker. Unusual Machines appears closest to the specific reported funding discussion among the listed public names. Red Cat, Ondas, Kratos and AeroVironment are better understood as sector beneficiaries unless direct funding, contracts or Office of Strategic Capital support are confirmed by filings, official releases or named government awards.
USA–Israel–Iran: the war enters the most dangerous phase, the armed ceasefire
Fresh U.S. strikes against Iranian targets, Tehran’s retaliation, tankers leaving Hormuz with transponders off and renewed pressure on oil prices: de-escalation remains possible, but markets are pricing a fragile, opaque and highly vulnerable ceasefire.
ASCO 2026 Investor Calendar: 25 Key Oncology Presentations, Dates, Times and Webcasts to Track
ASCO 2026 runs from May 29 to June 2, 2026 in Chicago and online. Regular abstract text was released before the meeting, while ASCO states that late-breaking abstracts, including plenary LBAs, are released at 7:00 AM CT / 8:00 AM ET on the day of their presentation. That timing matters because some of the most important market reactions may begin before the actual oral presentation if the abstract text contains enough clinical detail.
Three Biotech Data Presentations to Watch: Precision BioSciences, Lipocine and Citius Oncology $DTIL $LPCN $CTOR
Biotech traders do not need every conference appearance. They need the few events where a company is putting clinical data in front of a specialized audience, where the data may change the investor debate, and where the stock can react not only to the headline but to the details underneath it. On May 27, 2026, the cleanest U.S.-listed “data presentation” group is not a single mega-cap oncology story. It is a smaller, more speculative three-name basket: Precision BioSciences, Lipocine and Citius Oncology.
Artiva Biotherapeutics, Inc. (Nasdaq: $ARTV): EULAR, AlloNK and the Institutional Read-Through Ahead of the Next Catalyst
Artiva has moved from a quiet NK-cell platform story into a high-conviction autoimmune catalyst setup. The question now is not whether the early AlloNK signal is interesting. The question is whether EULAR 2026 and the planned registrational Phase 3 path can support the level of institutional attention that arrived after the May financing.
SpaceX IPO Filing Puts the New Space Trade Back in Motion — Why $RKLB, $RDW and $ASTS Moved Today
The SpaceX IPO filing has turned into a market-wide valuation event for the space sector. The most important point is not that SpaceX is going public — that had already been widely expected — but that the filing gives investors a new, highly visible reference point for how public markets may price the combined story of reusable launch, Starlink connectivity, satellite infrastructure, defense-linked space services, orbital logistics and long-duration AI/compute ambitions.
Biotech Catalyst Watch: Phase 2 IgAN Start, CRB-701 Cancer Data And Cullinan Autoimmune Updates $JBIO $CRBP $CGEM
Three official biotech updates from May 26, 2026 highlight different development stages: Jade Biosciences dosed the first participant in a Phase 2 IgA nephropathy study, Corbus updated Phase 1/2 data for its Nectin-4 ADC CRB-701, and Cullinan set an Immunology Day around CLN-978 and velinotamig in autoimmune diseases.
Healthcare Catalyst Watch: RenovoRx ASCO Data, Axsome AUVELITY Updates, Olema-Bayer Trial Deal $RNXT $AXSM $OLMA
Merlintrader Healthcare Focus Published: May 26, 2026 Conference and collaboration catalysts $RNXT $AXSM $OLMA EN IT Healthcare Catalyst Watch: RenovoRx ASCO Data, Axsome AUVELITY Updates, Olema-Bayer Trial Deal $RNXT $AXSM $OLMA Three official healthcare updates from May 26, 2026 show…
Biotech Catalyst Watch: Dyne Files BLA, NervGen Reports Neural Recovery Data, BriaCell Gets DSMB Green Light $DYN $NGEN $BCTX
The biotech tape on May 26, 2026 delivered three very different but clearly catalyst-driven updates. Dyne Therapeutics announced the submission of a Biologics License Application to the U.S. FDA for zeleciment rostudirsen, also known as z-rostudirsen or DYNE-251, in Duchenne muscular dystrophy patients amenable to exon 51 skipping. NervGen Pharma reported positive independent, blinded biomechanical gait analyses from the Phase 1b/2a CONNECT SCI study of NVG-291 in chronic spinal cord injury. BriaCell Therapeutics announced that an independent Data Safety Monitoring Board issued its sixth consecutive positive recommendation for the pivotal Phase 3 Bria-ABC study in metastatic breast cancer.
Karyopharm’s ASCO Moment: Can a Mixed Phase 3 Still Become a Myelofibrosis Story? $KPTI
Karyopharm is heading into ASCO 2026 with one of the more debate-friendly biotech setups of the week: a Phase 3 myelofibrosis trial that hit spleen-volume reduction, missed its symptom co-primary endpoint, showed a company-described promising survival signal, and may still feed into an FDA discussion for a possible sNDA path.
Three Near-Term Biotech Catalysts To Watch: Nuvalent, Legend Biotech and Zenas BioPharma $NUVL $LEGN $ZBIO
ASCO and EULAR are about to put three very different clinical stories in front of investors: a registrational ALK lung-cancer dataset already used for an NDA submission, an early solid-tumor CAR-T update from a commercial cell-therapy company, and a Phase 3 autoimmune dataset that could shape an upcoming regulatory filing.
Rental Car Sector Deep Dive — Summer Travel 2026 Outlook: Avis Budget, Hertz and Sixt ($CAR $HTZ $SIX2)
The summer travel 2026 rental-car trade is not as clean as the hotel or airline trade, but it may be even more useful for investors because it sits directly at the intersection of airports, road trips, leisure budgets, business mobility, fleet prices, used-car residual values and consumer sensitivity to gasoline.
Hilton, Marriott and Wyndham: Hotel Sector Deep Dive for the 2026 Summer Travel Season $HLT $MAR $WH
A long-form look at the lodging cycle before the peak vacation season: RevPAR, occupancy, ADR, loyalty ecosystems, bookings, destinations, pipelines, balance sheets and the different risk/reward profiles behind three major publicly traded hotel companies.
American Airlines, Delta Air Lines and United Airlines: Summer 2026 Sector Deep Dive ($AAL $DAL $UAL)
A complete bilingual sector report on the three U.S. listed airline majors ahead of the vacation season: demand, load factor, bookings, destinations, fuel, margins, balance sheet quality and the difference between full aircraft and profitable aircraft.
Russell 2026 Reconstitution: Why the Preliminary Russell 2000 Adds Matter for Traders $ONDS $LPTH $IMRX $OCGN
Key point: FTSE Russell’s preliminary 2026 reconstitution list shows 237 companies joining the Russell 2000 Index. The list is preliminary, not final. Updates are scheduled before the final implementation after the U.S. market close on June 26, 2026, with updated membership reflected from the open on June 29, 2026.
Hyliion Holdings Corp. (NYSE American: $HYLN): The KARNO Pivot, Navy Validation, Data Center Optionality and the Real Execution Test Ahead
A full single-stock deep dive on Hyliion’s transition from electric powertrains to modular fuel-agnostic power generation, with a focus on Q1 2026 results, KARNO commercialization, U.S. Navy activity, data center demand, liquidity, risks, catalysts and trading setup.
Artelo Biosciences (Nasdaq: $ARTL) — May 2026 Deep Dive: FABP5 Pain Catalyst, ART27.13 Optionality, Balance-Sheet Reset and Dilution Reality
A single-stock May 2026 review of Artelo’s story from the earlier CAReS and FABP5 setup to the latest Q1 business update, the ScienceMachine collaboration, the glaucoma expansion, the GLP-1 companion angle, the $11 million financing, the Nasdaq compliance repair and the still-visible common-equity risks.
